{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:07:29Z","timestamp":1761919649500,"version":"3.40.4"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.2515\/therapie\/2012036","type":"journal-article","created":{"date-parts":[[2012,10,31]],"date-time":"2012-10-31T09:38:42Z","timestamp":1351676322000},"page":"381-390","source":"Crossref","is-referenced-by-count":12,"title":["Suivi th\u00e9rapeutique pharmacologique de la primidone et du ph\u00e9nobarbital"],"prefix":"10.1016","volume":"67","author":[{"given":"Dani\u00e8le","family":"Bentu\u00e9-Ferrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Cl\u00e9mence","family":"Verdier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Tribut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9445","key":"10.2515\/therapie\/2012036_bb1115","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(04)17306-6","article-title":"Discontinuation of Mysoline: lessons to be learned","volume":"64","author":"Reuber","year":"2004","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2012036_bb1120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.seizure.2005.10.002","article-title":"Is primidone the drug of choice for epileptic patients with QT-prolongation? A comprehensive analysis of literature","volume":"15","author":"Christidis","year":"2006","journal-title":"Seizure"},{"key":"10.2515\/therapie\/2012036_bb1125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1474-4422(10)70322-7","article-title":"Treatment of patients with essential tremor","volume":"10","author":"Deuschl","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.2515\/therapie\/2012036_bb1130","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2165\/0023210-200822120-00006","article-title":"Pharmacotherapy of essential tremor : an overview of existing and upcoming agents","volume":"22","author":"Lyons","year":"2008","journal-title":"CNS Drugs"},{"key":"10.2515\/therapie\/2012036_bb1135","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/WNL.22.11.1186","article-title":"Metabolic disposition of primidone and its metabolites in epileptic subjects after single and repeated administration","volume":"22","author":"Gallagher","year":"1972","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2012036_bb1140","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0022-3476(84)80442-4","article-title":"Primidone therapy in refractory neonatal seizures","volume":"105","author":"Powell","year":"1984","journal-title":"J Pediatr"},{"key":"10.2515\/therapie\/2012036_bb1145","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/cpt1977222200","article-title":"Kinetics of primidone metabolism and excretion in children","volume":"22","author":"Kauffman","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2012036_bb1150","series-title":"Antiepileptic drugs: quantitative analysis and interpr\u00e9tation","first-page":"273","article-title":"Clinical application of serum primidone levels","author":"Schottelius","year":"1978"},{"key":"10.2515\/therapie\/2012036_bb1155","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000457682","article-title":"Primidone and phenobarbital during lactation period in epileptic women: total and free drug serum levels in the nursed infants and their effects on neonatal behavior","volume":"11","author":"Kuhnz","year":"1988","journal-title":"Dev Pharmacol Ther"},{"key":"10.2515\/therapie\/2012036_bb1160","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1600-0404.1987.tb05455.x","article-title":"Primidone and propranolol in essential tremor: a study based on quantitative tremor recording and plasma anticonvulsant levels","volume":"75","author":"Dietrichson","year":"1987","journal-title":"Acta Neurol Scand"},{"key":"10.2515\/therapie\/2012036_bb1165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1353-8020(03)00070-1","article-title":"Use of primidone in low doses (250 mg\/day) versus high doses (750 mg\/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up","volume":"10","author":"Serrano-Duenas","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"key":"10.2515\/therapie\/2012036_bb1170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1212\/WNL.36.1.121","article-title":"Efficacy of primidone in essential tremor","volume":"36","author":"Koller","year":"1986","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2012036_bb1175","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/jnnp.44.10.932","article-title":"Phenylethylmalonamide in essential tremor. A double-blind controlled study","volume":"44","author":"Calzetti","year":"1981","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.2515\/therapie\/2012036_bb1180","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/j.1528-1157.2000.tb04610.x","article-title":"The \u201cforgotten\u201d cross-tolerance between phenobarbital and primidone: it can prevent acute primidone-related toxicity","volume":"41","author":"Kanner","year":"2000","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012036_bb1185","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1528-1157.1970.tb03905.x","article-title":"A clinical study of serum primidone levels","volume":"11","author":"Booker","year":"1970","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012036_bb1190","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00007691-198303000-00006","article-title":"Plasma levels of primidone and its metabolite phenobarbital: effect of age and associated therapy","volume":"5","author":"Battino","year":"1983","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1195","first-page":"123","article-title":"How worthwhile is plasma primidone level measurement?","volume":"18","author":"Eadie","year":"1981","journal-title":"Clin Exp Neurol"},{"key":"10.2515\/therapie\/2012036_bb1200","first-page":"185","article-title":"PB:PRM ratio in patients with epilepsy treated with primidone","volume":"3","author":"Cornaggia","year":"1983","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.2515\/therapie\/2012036_bb1205","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2125.1990.tb03820.x","article-title":"The disposition of primidone in elderly patients","volume":"30","author":"Martines","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2012036_bb1210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2165\/00003088-198409030-00006","article-title":"Changes in primidone\/phenobarbitone ratio during pregnancy and the puerperium","volume":"9","author":"Battino","year":"1984","journal-title":"Clin Pharmacokinet"},{"key":"10.2515\/therapie\/2012036_bb1215","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1651-2227.1982.tb09418.x","article-title":"Teratogenic and pharmacokinetic studies of primidone during pregnancy and in the offspring of epileptic women","volume":"71","author":"Rating","year":"1982","journal-title":"Acta Paediatr Scand"},{"key":"10.2515\/therapie\/2012036_bb1220","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00561476","article-title":"Placental transfer and pharmacokinetics of primidone and its metabolites phenobarbital, PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers","volume":"18","author":"Nau","year":"1980","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2012036_bb1225","first-page":"165","article-title":"Primidone-carbamazepine interaction: clinical consequences","volume":"7","author":"Benetello","year":"1987","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.2515\/therapie\/2012036_bb1230","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00314604","article-title":"The effect of phenytoin and ethosuximide on primidone metabolism in patients with epilepsy","volume":"209","author":"Schmidt","year":"1975","journal-title":"J Neurol"},{"issue":"5971","key":"10.2515\/therapie\/2012036_bb1235","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/bmj.2.5971.594","article-title":"Interaction of phenytoin and primidone","volume":"2","author":"Reynolds","year":"1975","journal-title":"Br Med J"},{"key":"10.2515\/therapie\/2012036_bb1240","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1248\/bpb1978.15.467","article-title":"Single-dose kinetics of primidone in human subjects: effect of phenytoin on formation and elimination of active metabolites of primidone, phenobarbital and phenylethylmalonamide","volume":"15","author":"Sato","year":"1992","journal-title":"J Pharmacobiodyn"},{"key":"10.2515\/therapie\/2012036_bb1245","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2710.1989.tb00261.x","article-title":"The effect of concurrent administration of sodium valproate on serum levels of primidone and its metabolite phenobarbital","volume":"14","author":"Yukawa","year":"1989","journal-title":"J Clin Pharm Ther"},{"key":"10.2515\/therapie\/2012036_bb1250","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archneur.1974.00490330067012","article-title":"The influence of diphenylhydantoin on primidone metabolism","volume":"30","author":"Fincham","year":"1974","journal-title":"Arch Neurol"},{"key":"10.2515\/therapie\/2012036_bb1255","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0022-3476(73)80282-3","article-title":"Chronic and severe phenobarbital intoxication in a child treated with primidone and diphenylhydantoin","volume":"83","author":"Wilson","year":"1973","journal-title":"J Pediatr"},{"key":"10.2515\/therapie\/2012036_bb1260","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-0028-1091502","article-title":"Drug interactions during anticonvulsant therapy in childhood: diphenylhydantoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepin and dipropylacetate","volume":"8","author":"Windorfer","year":"1977","journal-title":"Neuropediatrie"},{"key":"10.2515\/therapie\/2012036_bb1265","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1212\/WNL.32.10.1122","article-title":"Interactions between primidone, carbamazepine, and nicotinamide","volume":"32","author":"Bourgeois","year":"1982","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2012036_bb1270","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1212\/WNL.25.12.1179","article-title":"Isoniazid as an inhibitor of primidone metabolism","volume":"25","author":"Sutton","year":"1975","journal-title":"Neurology"},{"year":"2011","series-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit primidone: \u00c9ditions du Vidal","key":"10.2515\/therapie\/2012036_bb1275"},{"key":"10.2515\/therapie\/2012036_bb1280","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00007691-199910000-00013","article-title":"Liquid chromatographic determination of six antiepileptic drugs and two metabolites in microsamples of human plasma","volume":"21","author":"Matar","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1285","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00007691-199402000-00015","article-title":"Simultaneous determination of felbamate, primidone, phenobarbital, carbamazepine, two carbamazepine metabolites, phenytoin, and one phenytoin metabolite in human plasma by high-performance liquid chromatography","volume":"16","author":"Romanyshyn","year":"1994","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1290","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/clinchem\/30.10.1667","article-title":"Simultaneous measurement of ethosuximide, primidone, phenobarbital, phenytoin, carbamazepine, and their bioactive metabolites by liquid chromatography","volume":"30","author":"Ou","year":"1984","journal-title":"Clin Chem"},{"key":"10.2515\/therapie\/2012036_bb1295","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jchromb.2007.06.023","article-title":"Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction","volume":"857","author":"Vermeij","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.2515\/therapie\/2012036_bb1300","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/FTD.0b013e3181c324c8","article-title":"A novel HPLC method for quantification of 10 antiepileptic drugs or metabolites in serum\/plasma using a monolithic column","volume":"32","author":"Heideloff","year":"2010","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jssc.200700253","article-title":"Simultaneous determination of antiepileptic drugs and their two active metabolites by HPLC","volume":"31","author":"Budakova","year":"2008","journal-title":"J Sep Sci"},{"key":"10.2515\/therapie\/2012036_bb1310","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00007691-199308000-00009","article-title":"Determination of phenobarbital, ethosuximide, and primidone in human serum by micellar electrokinetic capillary chromatography with direct sample injection","volume":"15","author":"Schmutz","year":"1993","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1315","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0378-4347(00)81652-7","article-title":"Microassay for primidone and its metabolites phenylethylmalondiamide, phenobarbital and p-hydroxyphenobarbital in human serum, saliva, breast milk and tissues by gas chromatography--mass spectrometry using selected ion monitoring","volume":"182","author":"Nau","year":"1980","journal-title":"J Chromatogr"},{"key":"10.2515\/therapie\/2012036_bb1320","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012036_bb1325","first-page":"21","article-title":"M\u00e9thodologie pour l\u2019\u00e9valuation du niveau de preuve du suivi th\u00e9rapeutique pharmacologique","volume":"23","author":"Le Guellec","year":"2009","journal-title":"La Lettre du Pharmacologue"},{"key":"10.2515\/therapie\/2012036_bb1330","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pediatrneurol.2007.04.003","article-title":"Neonatal seizures: multicenter variability in current treatment practices","volume":"37","author":"Bartha","year":"2007","journal-title":"Pediatr Neurol"},{"key":"10.2515\/therapie\/2012036_bb1335","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.emc.2010.08.005","article-title":"Generalized convulsive status epilepticus in adults and children: treatment guidelines and protocols","volume":"29","author":"Shearer","year":"2011","journal-title":"Emerg Med Clin North Am"},{"year":"2011","series-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit ph\u00e9nobarbital","key":"10.2515\/therapie\/2012036_bb1340"},{"key":"10.2515\/therapie\/2012036_bb1345","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF01061382","article-title":"Kinetics of phenobarbital in normal subjects and epileptic patients","volume":"23","author":"Wilensky","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2012036_bb1350","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2710.1993.tb00586.x","article-title":"Dosage programming of phenobarbital in neonatal seizures","volume":"18","author":"Alonso Gonzalez","year":"1993","journal-title":"J Clin Pharm Ther"},{"key":"10.2515\/therapie\/2012036_bb1355","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00007691-200106000-00005","article-title":"Pharmacokinetics of phenobarbital during certain enhanced elimination modalities to evaluate their clinical efficacy in management of drug overdose","volume":"23","author":"Mohammed Ebid","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1360","first-page":"117","article-title":"Serum concentrations of diphenylhydantoin (phenytoin) and phenobarbital and their relation to therapeutic and toxic effects","volume":"74","author":"Buchthal","year":"1971","journal-title":"Psychiatr Neurol Neurochir"},{"key":"10.2515\/therapie\/2012036_bb1365","series-title":"Antiepileptic drugs","first-page":"329","article-title":"Phenobarbital, mephobarbital, and metharbital. Relation of plasma levels to clinical control","author":"Booker","year":"1972"},{"key":"10.2515\/therapie\/2012036_bb1370","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/j.1552-4604.1976.tb01491.x","article-title":"The relation of anticonvulsant drug levels to complete seizure control","volume":"16","author":"Feldman","year":"1976","journal-title":"J Clin Pharmacol"},{"key":"10.2515\/therapie\/2012036_bb1375","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/archneur.1986.00520030053013","article-title":"The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital, and carbamazepine","volume":"43","author":"Schmidt","year":"1986","journal-title":"Arch Neurol"},{"key":"10.2515\/therapie\/2012036_bb1380","first-page":"18","article-title":"Monitoring of phenobarbitone in epileptic children","volume":"25","author":"Singh","year":"1987","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.2515\/therapie\/2012036_bb1385","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1528-1157.2000.tb00144.x","article-title":"A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy","volume":"41","author":"Jannuzzi","year":"2000","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012036_bb1390","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5414\/CPP45121","article-title":"Evaluation of therapeutic drug level monitoring of phenobarbital, phenytoin and carbamazepine in Iranian epileptic patients","volume":"45","author":"Babaei","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2012036_bb1395","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00007691-198406000-00009","article-title":"Variability of plasma phenobarbitone concentration in Asian children in Singapore","volume":"6","author":"Lee","year":"1984","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1400","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1528-1157.1988.tb04408.x","article-title":"If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study","volume":"29","author":"Woo","year":"1988","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012036_bb1405","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jama.1975.03250010042028","article-title":"Anticonvulsant drug blood levels","volume":"232","author":"Livingston","year":"1975","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2012036_bb1410","series-title":"Antiepileptic Drugs","first-page":"335","article-title":"Phenobarbital. Relation of serum concentration to control of seizure","author":"Buchthal","year":"1972"},{"key":"10.2515\/therapie\/2012036_bb1415","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1528-1157.1984.tb04160.x","article-title":"Effectiveness and toxicity of phenobarbital, primidone, and sodium valproate in the prevention of febrile convulsions, controlled by plasma levels","volume":"25","author":"Herranz","year":"1984","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012036_bb1420","first-page":"111","article-title":"Phenobarbital plasma levels in neonates","volume":"2","author":"Pippenger","year":"1975","journal-title":"Clin Perinatol"},{"key":"10.2515\/therapie\/2012036_bb1425","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.pediatrneurol.2005.11.001","article-title":"Plasma levels of antiepileptic drugs in children on the ketogenic diet","volume":"35","author":"Dahlin","year":"2006","journal-title":"Pediatr Neurol"},{"key":"10.2515\/therapie\/2012036_bb1430","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0404.2010.01359.x","article-title":"Valproic acid and phenobarbital blood levels during the first month of treatment with the ketogenic diet","volume":"122","author":"Coppola","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.2515\/therapie\/2012036_bb1435","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1528-1167.2011.02978.x","article-title":"Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: A pharmacokinetic study during whole body hypothermia","volume":"52","author":"Filippi","year":"2011","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012036_bb1440","first-page":"318","article-title":"Developmental aspects of phenobarbital dosage requirements in newborn infants with seizures","volume":"8","author":"Nahata","year":"1988","journal-title":"J Perinatol"},{"key":"10.2515\/therapie\/2012036_bb1445","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2125.1977.tb00783.x","article-title":"Factors influencing plasma phenobarbitone levels in epileptic patients","volume":"4","author":"Eadie","year":"1977","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2012036_bb1450","first-page":"337","article-title":"Phenobarbital plasma level\/dose ratio in monotherapy. Influence of age, sex and dose","volume":"10","author":"Duran","year":"1988","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.2515\/therapie\/2012036_bb1455","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2710.1992.tb01301.x","article-title":"Influence of age and co-medication on steady-state phenobarbital serum level-dose ratios in Japanese paediatric patients","volume":"17","author":"Yukawa","year":"1992","journal-title":"J Clin Pharm Ther"},{"key":"10.2515\/therapie\/2012036_bb1460","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.0013-9580.2005.47504.x","article-title":"Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data","volume":"46","author":"Messina","year":"2005","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012036_bb1465","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.ftd.0000155342.93489.fd","article-title":"10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs","volume":"27","author":"Armijo","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1470","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2125.1993.tb00378.x","article-title":"The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid","volume":"36","author":"Tartara","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2012036_bb1475","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00007691-199103000-00004","article-title":"Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine","volume":"13","author":"Spina","year":"1991","journal-title":"Ther Drug Monit"},{"year":"2012","series-title":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit de la lamotrigine","key":"10.2515\/therapie\/2012036_bb1480"},{"key":"10.2515\/therapie\/2012036_bb1485","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1528-1167.2007.00983.x","article-title":"Pharmacokinetics and drug interactions with zonisamide","volume":"48","author":"Sills","year":"2007","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012036_bb1490","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00007691-200406000-00005","article-title":"Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications","volume":"26","author":"Adin","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1495","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00007691-200206000-00007","article-title":"Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication","volume":"24","author":"May","year":"2002","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1500","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0920-1211(95)00048-8","article-title":"Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs","volume":"22","author":"So","year":"1995","journal-title":"Epilepsy Res"},{"key":"10.2515\/therapie\/2012036_bb1505","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00007691-200408000-00006","article-title":"Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs","volume":"26","author":"Contin","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1510","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2125.1991.tb05507.x","article-title":"Lack of a pharmacokinetic interaction between phenobarbitone and gabapentin","volume":"31","author":"Hooper","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2012036_bb1515","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/jnnp.44.2.148","article-title":"The effects of phenytoin on phenobarbitone and primidone metabolism","volume":"44","author":"Lambie","year":"1981","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.2515\/therapie\/2012036_bb1520","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00007691-198612000-00006","article-title":"Effect of sodium valproate on phenobarbital serum levels in children and adults","volume":"8","author":"Fernandez de Gatta","year":"1986","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1525","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1248\/bpb.27.2000","article-title":"Influence of coadministered antiepileptic drugs on serum phenobarbital concentrations in epileptic patients: quantitative analysis based on a suitable transforming factor","volume":"27","author":"Fukuoka","year":"2004","journal-title":"Biol Pharm Bull"},{"key":"10.2515\/therapie\/2012036_bb1530","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0009-9236(95)90244-9","article-title":"Effects of felbamate on the pharmacokinetics of phenobarbital","volume":"58","author":"Reidenberg","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2012036_bb1535","first-page":"165","article-title":"Neurophysiological and therapeutic evaluation of stiripentol in epilepsy. Preliminary results","volume":"144","author":"Loiseau","year":"1988","journal-title":"Rev Neurol (Paris)"},{"key":"10.2515\/therapie\/2012036_bb1540","first-page":"107","article-title":"Vigabatrin-plasma enantiomer concentrations and clinical effects","volume":"29","author":"Sheean","year":"1992","journal-title":"Clin Exp Neurol"},{"key":"10.2515\/therapie\/2012036_bb1545","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1528-1167.2010.02763.x","article-title":"Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine","volume":"52","author":"Bockbrader","year":"2011","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2012036_bb1550","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1586\/ecp.10.3","article-title":"Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives","volume":"3","author":"Reddy","year":"2010","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.2515\/therapie\/2012036_bb1555","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3565(25)21041-2","article-title":"Effects of chronic phenobarbital on verapamil disposition in humans","volume":"246","author":"Rutledge","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.2515\/therapie\/2012036_bb1560","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/0897190010377804","article-title":"Clinically significant drug-drug interaction between tacrolimus and phenobarbital: the price we pay","volume":"23","author":"Siddiqi","year":"2010","journal-title":"J Pharm Pract"},{"key":"10.2515\/therapie\/2012036_bb1565","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ana.22229","article-title":"Antiepileptic drugs interact with folate and vitamin B12 serum levels","volume":"69","author":"Linnebank","year":"2011","journal-title":"Ann Neurol"},{"key":"10.2515\/therapie\/2012036_bb1570","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/bdd.284","article-title":"Effect of smoking on single dose pharmacokinetics of phenobarbital","volume":"22","author":"Mirfazaelian","year":"2001","journal-title":"Biopharm Drug Dispos"},{"key":"10.2515\/therapie\/2012036_bb1575","doi-asserted-by":"crossref","first-page":"568","DOI":"10.7326\/0003-4819-101-4-568_2","article-title":"Phenytoin and phenobarbital concentrations in renal insufficiency","volume":"101","author":"Turk","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.2515\/therapie\/2012036_bb1580","first-page":"763","article-title":"Validated high performance liquid chromatographic method for simultaneous determination of phenytoin, phenobarbital and carbamazepine in human serum","volume":"53","author":"Kishore","year":"2003","journal-title":"Arzneimittelforschung"},{"key":"10.2515\/therapie\/2012036_bb1585","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0378-4347(93)80477-L","article-title":"Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high-performance liquid chromatography with photodiode-array detection","volume":"616","author":"Liu","year":"1993","journal-title":"J Chromatogr"},{"key":"10.2515\/therapie\/2012036_bb1590","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.2726","article-title":"Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring","author":"Shibata","year":"2012","journal-title":"Biomed Chromatogr"},{"key":"10.2515\/therapie\/2012036_bb1595","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00007691-199103000-00013","article-title":"Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva","volume":"13","author":"Miles","year":"1991","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1600","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF00439247","article-title":"Correlation between the saliva and free serum concentration of phenobarbital in epileptic children","volume":"145","author":"Tokugawa","year":"1986","journal-title":"Eur J Pediatr"},{"key":"10.2515\/therapie\/2012036_bb1605","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00007691-198103000-00008","article-title":"Monitoring of phenobarbitone and phenytoin therapy in small children by salivary samples","volume":"3","author":"Mucklow","year":"1981","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2012036_bb1610","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00007691-198204000-00009","article-title":"Phenobarbital pharmacokinetics and salivary and serum concentrations in pregnancy","volume":"4","author":"Luoma","year":"1982","journal-title":"Ther Drug Monit"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716308460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716308460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T00:31:51Z","timestamp":1745109111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716308460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0040595716308460"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2012036","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}